-
Mashup Score: 2
CEO Michael Davidson describes how Obicetrapib, which was reacquired from Amgen, is designed to produce more LDL lowering than other assets in the class.
Source: www.biotechtv.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 8
CEO Michael Davidson describes how Obicetrapib, which was reacquired from Amgen, is designed to produce more LDL lowering than other assets in the class.
Source: www.biotechtv.comCategories: General Medicine News, CardiologistsTweet-
RT @mdavidsonmd: My biotech TV interview about the history of New Amsterdam Pharma and Obicetrapib https://t.co/2Q8xtm4OlF
-
RT @mdavidsonmd: My biotech TV interview about the history of New Amsterdam Pharma and Obicetrapib https://t.co/2Q8xtm4OlF